Compare PLRX & WWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | WWR |
|---|---|---|
| Founded | 2015 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 76.7M |
| IPO Year | 2020 | 2006 |
| Metric | PLRX | WWR |
|---|---|---|
| Price | $1.24 | $0.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $2.67 | $1.92 |
| AVG Volume (30 Days) | 547.4K | ★ 873.6K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $0.45 |
| 52 Week High | $1.95 | $3.75 |
| Indicator | PLRX | WWR |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 46.30 |
| Support Level | $1.13 | $0.58 |
| Resistance Level | $1.37 | $0.73 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 31.82 | 49.06 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.